RxDoctor Payments Data

Alexandra Levitt, MD

Ophthalmic Plastic and Reconstructive Surgery · Denver, CONPI 1558711499

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 74 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 14 manufacturers, the largest accounting for just 19.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,684 and has fallen 52.4% since, to $802 in 2025.

$4,583in general payments, 2019–2025

Across 74 payments — averaging $61.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$911
  • Alcon$892
  • Amgen$716
  • Mallinckrodt Enterprises LLC$475
  • Stryker$351
  • Genentech USA, Inc.$272
  • plus $967 from 8 others

What the payments were for

  • Food & beverage$4,583100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,583 in reported general payments places this provider in the 85th percentile of 21 ophthalmic plastic and reconstructive surgery providers in Colorado.

See all ophthalmic plastic and reconstructive surgery providers in Colorado

Medicare billing

Part B allowed, 2024
$152,130
Medicare patients
254
Services billed
1,578

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha174$2,118
Fluorometholone27$1,897
ErythromycinErythromycin Base80$1,060
Tobramycin-DexamethasoneTobramycin/Dexamethasone13$503
Bacitracin-PolymyxinBacitracin/Polymyxin B Sulfate28$404
Tramadol Hcl130$270
Cephalexin15$170
Fluticasone Propionate11$136
Methylprednisolone17$120
Prednisone12$88
Alprazolam16$23
Promethazine Hcl11$23

Paid to pharmacies, not to this prescriber.

Other ophthalmic plastic and reconstructive surgery in Denver

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →